Cidofovir: Difference between revisions
From IDWiki
(Created page with "* Cytosine nucleotide analogue that inhibits DNA polymerase in human herpesviruses * Unlike ganciclovir, it does ''not'' need phosphorylation by UL97 * Indications: {{...") |
No edit summary |
||
| Line 1: | Line 1: | ||
* Cytosine nucleotide analogue that inhibits DNA polymerase in [[human herpesviruses]] |
* Cytosine nucleotide analogue that inhibits DNA polymerase in [[human herpesviruses]] |
||
| + | * Should be given with [[probenecid]] 2 g IV prior to each dose |
||
* Unlike [[ganciclovir]], it does ''not'' need phosphorylation by UL97 |
* Unlike [[ganciclovir]], it does ''not'' need phosphorylation by UL97 |
||
* Indications: {{#ask: [[Is treated by::cidofovir]] | default=none}} |
* Indications: {{#ask: [[Is treated by::cidofovir]] | default=none}} |
||
| + | * Major adverse effect is irreversible renal tubular necrosis, which may be prevented by probenecid |
||
[[Category:Antivirals]] |
[[Category:Antivirals]] |
||
Revision as of 22:03, 23 October 2019
- Cytosine nucleotide analogue that inhibits DNA polymerase in human herpesviruses
- Should be given with probenecid 2 g IV prior to each dose
- Unlike ganciclovir, it does not need phosphorylation by UL97
- Indications: Adenovirus, CMV after solid organ transplantation, Cytomegalovirus, Herpes simplex virus
- Major adverse effect is irreversible renal tubular necrosis, which may be prevented by probenecid
